• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

AZ delivers 1.8m doses ahead of mass rollout

firstwordpharmaJune 07, 2021

Tag: AstraZeneca , COVID-19 , Vaccine

Thailand's publish health ministry said AstraZeneca delivered 1.8 million locally produced COVID-19 vaccine doses, the first of 6 million scheduled for delivery this month, reported the Bangkok Post.

AZ delivers 1.8m doses ahead of mass rollout

AstraZeneca said it started receiving deliveries from its authorised producer Siam Bioscience last week.

James Teague, AstraZeneca's country president, said the delivery was significant and marked the start of a sustainable supply of the vaccine in Thailand.

The company would be able to supply the vaccine as scheduled in Thailand, and begin shipments to other Asean countries in July, he said.

Previous:South Korea's IP laws key to expanding COVID-19 vaccine partnership: US senators

Next:Dr Reddy’s recalls 2,980 bottles of Atorvastatin Calcium tablets in US

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

AZ delivers 1.8m doses ahead of mass rollout | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Inactivated Influenza Vaccine(Split Virion) manufactured by Hualan Bio

Inactivated Influenza Vaccine(Split Virion) manufactured by Hualan Bio
high standard and safety Influenza A (H1N1) Vaccine, (Split, Inactivated)

high standard and safety Influenza A (H1N1) Vaccine, (Split, Inactivated)
2023-2024 flu vaccine

2023-2024 flu vaccine
Hualan's Influenza Vaccine

Hualan's Influenza Vaccine
Hualan's Trivalent Flu Vaccine

Hualan's Trivalent Flu Vaccine
H7N9 Inactivated Influenza Vaccine-HUALAN BIO

H7N9 Inactivated Influenza Vaccine-HUALAN BIO
Influenza Vaccine (Split virion)

Influenza Vaccine (Split virion)
Hualan's Group ACYW135 Meningococcal Polysaccharide Vaccine

Hualan's Group ACYW135 Meningococcal Polysaccharide Vaccine
Meningococcal Polysaccharide Vaccine Group ACYW135

Meningococcal Polysaccharide Vaccine Group ACYW135
Group A and C Meningococcal+Haemophilus Type B Conjugate Vaccine

Group A and C Meningococcal+Haemophilus Type B Conjugate Vaccine

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service